| Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials MJ Sorich, MD Wiese, A Rowland, G Kichenadasse, RA McKinnon, ... Annals of Oncology 26 (1), 13-21, 2015 | 609 | 2015 |
| Patient barriers to and enablers of deprescribing: a systematic review E Reeve, J To, I Hendrix, S Shakib, MS Roberts, MD Wiese Drugs & aging 30, 793-807, 2013 | 523 | 2013 |
| Review of deprescribing processes and development of an evidence‐based, patient‐centred deprescribing process E Reeve, S Shakib, I Hendrix, MS Roberts, MD Wiese British journal of clinical pharmacology 78 (4), 738-747, 2014 | 383 | 2014 |
| Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer A Rowland, MM Dias, MD Wiese, G Kichenadasse, RA McKinnon, ... British journal of cancer 112 (12), 1888-1894, 2015 | 380 | 2015 |
| People's attitudes, beliefs, and experiences regarding polypharmacy and willingness to deprescribe E Reeve, MD Wiese, I Hendrix, MS Roberts, S Shakib Journal of the American Geriatrics Society 61 (9), 1508-1514, 2013 | 268 | 2013 |
| Clinical outcomes associated with medication regimen complexity in older people: a systematic review BC Wimmer, AJ Cross, N Jokanovic, MD Wiese, J George, K Johnell, ... Journal of the American Geriatrics Society 65 (4), 747-753, 2017 | 233 | 2017 |
| Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers AM Hopkins, A Rowland, G Kichenadasse, MD Wiese, H Gurney, ... British journal of cancer 117 (7), 913-920, 2017 | 175 | 2017 |
| Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial SGA Brown, MD Wiese, KE Blackman, RJ Heddle The Lancet 361 (9362), 1001-1006, 2003 | 156 | 2003 |
| Medication regimen complexity and polypharmacy as factors associated with all-cause mortality in older people: a population-based cohort study BC Wimmer, JS Bell, J Fastbom, MD Wiese, K Johnell Annals of pharmacotherapy 50 (2), 89-95, 2016 | 147 | 2016 |
| CYP2C19 Genotype Has a Greater Effect on Adverse Cardiovascular Outcomes Following Percutaneous Coronary Intervention and in Asian Populations Treated … MJ Sorich, A Rowland, RA McKinnon, MD Wiese Circulation: cardiovascular genetics 7 (6), 895-902, 2014 | 142 | 2014 |
| The benefits and harms of deprescribing E Reeve, S Shakib, I Hendrix, MS Roberts, MD Wiese Medical journal of Australia 201 (7), 386-389, 2014 | 136 | 2014 |
| Development and validation of the patients’ attitudes towards deprescribing (PATD) questionnaire E Reeve, S Shakib, I Hendrix, MS Roberts, MD Wiese International journal of clinical pharmacy 35, 51-56, 2013 | 121 | 2013 |
| Benefits of deprescribing on patients’ adherence to medications E Reeve, MD Wiese International journal of clinical pharmacy 36, 26-29, 2014 | 114 | 2014 |
| Alterations in drug disposition in older adults E Reeve, MD Wiese, AA Mangoni Expert opinion on drug metabolism & toxicology 11 (4), 491-508, 2015 | 112 | 2015 |
| Feasibility of a patient-centered deprescribing process to reduce inappropriate use of proton pump inhibitors E Reeve, JM Andrews, MD Wiese, I Hendrix, MS Roberts, S Shakib Annals of Pharmacotherapy 49 (1), 29-38, 2015 | 94 | 2015 |
| Medication regimen complexity and number of medications as factors associated with unplanned hospitalizations in older people: a population-based cohort study BC Wimmer, JS Bell, J Fastbom, MD Wiese, K Johnell Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences …, 2016 | 83 | 2016 |
| Medication regimen complexity and unplanned hospital readmissions in older people BC Wimmer, E Dent, JS Bell, MD Wiese, I Chapman, K Johnell, ... Annals of Pharmacotherapy 48 (9), 1120-1128, 2014 | 74 | 2014 |
| Immediate‐type hypersensitivity drug reactions SF Stone, EJ Phillips, MD Wiese, RJ Heddle, SGA Brown British journal of clinical pharmacology 78 (1), 1-13, 2014 | 74 | 2014 |
| The validity of sequence symmetry analysis (SSA) for adverse drug reaction signal detection IA Wahab, NL Pratt, MD Wiese, LM Kalisch, EE Roughead Pharmacoepidemiology and drug safety 22 (5), 496-502, 2013 | 74 | 2013 |
| Characterisation of major peptides in ‘jack jumper’ant venom by mass spectrometry NW Davies, MD Wiese, SGA Brown Toxicon 43 (2), 173-183, 2004 | 73 | 2004 |
